Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 12/2023

25.11.2023 | Research

Comprehensive analysis of scRNA-Seq and bulk RNA-Seq data reveals dynamic changes in tumor-associated neutrophils in the tumor microenvironment of hepatocellular carcinoma and leads to the establishment of a neutrophil-related prognostic model

verfasst von: Dashuai Yang, Yu Zhou, Yanbing Zhang, Yang Su, Jie Shen, Bin Yu, Kailiang Zhao, Youming Ding

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 12/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Analysis of hepatocellular carcinoma (HCC) single-cell sequencing data was conducted to explore the role of tumor-associated neutrophils in the tumor microenvironment.

Methods

Analysis of single-cell sequencing data from 12 HCC tumor cores and five HCC paracancerous tissues identified cellular subpopulations and cellular marker genes. The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases were used to establish and validate prognostic models. xCELL, TIMER, QUANTISEQ, CIBERSORT, and CIBERSORT-abs analyses were performed to explore immune cell infiltration. Finally, the pattern of tumor-associated neutrophil roles in tumor microenvironmental components was explored.

Results

A total of 271 marker genes for tumor-associated neutrophils were identified based on single-cell sequencing data. Prognostic models incorporating eight genes were established based on TCGA data. Immune cell infiltration differed between the high- and low-risk groups. The low-risk group benefited more from immunotherapy. Single-cell analysis indicated that tumor-associated neutrophils were able to influence macrophage, NK cell, and T-cell functions through the IL16, IFN-II, and SPP1 signaling pathways.

Conclusion

Tumor-associated neutrophils regulate immune functions by influencing macrophages and NK cells. Models incorporating tumor-associated neutrophil-related genes can be used to predict patient prognosis and immunotherapy responses.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424CrossRefPubMed Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424CrossRefPubMed
2.
Zurück zum Zitat Huang DQ, Singal AG, Kono Y, Tan DJH, El-Serag HB, Loomba R (2022) Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab 34(7):969–77.e2PubMedPubMedCentralCrossRef Huang DQ, Singal AG, Kono Y, Tan DJH, El-Serag HB, Loomba R (2022) Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab 34(7):969–77.e2PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Liu Z, Jiang Y, Yuan H, Fang Q, Cai N, Suo C et al (2019) The trends in incidence of primary liver cancer caused by specific etiologies: results from the global burden of disease study 2016 and implications for liver cancer prevention. J Hepatol 70(4):674–683PubMedCrossRef Liu Z, Jiang Y, Yuan H, Fang Q, Cai N, Suo C et al (2019) The trends in incidence of primary liver cancer caused by specific etiologies: results from the global burden of disease study 2016 and implications for liver cancer prevention. J Hepatol 70(4):674–683PubMedCrossRef
5.
Zurück zum Zitat Grady WM, Yu M, Markowitz SD (2021) Epigenetic alterations in the gastrointestinal tract: current and emerging use for biomarkers of cancer. Gastroenterology 160(3):690–709PubMedCrossRef Grady WM, Yu M, Markowitz SD (2021) Epigenetic alterations in the gastrointestinal tract: current and emerging use for biomarkers of cancer. Gastroenterology 160(3):690–709PubMedCrossRef
6.
Zurück zum Zitat Chowdhury MMH, Salazar CJJ, Nurunnabi M (2021) Recent advances in bionanomaterials for liver cancer diagnosis and treatment. Biomaterials science 9(14):4821–4842PubMedCrossRef Chowdhury MMH, Salazar CJJ, Nurunnabi M (2021) Recent advances in bionanomaterials for liver cancer diagnosis and treatment. Biomaterials science 9(14):4821–4842PubMedCrossRef
7.
Zurück zum Zitat Zhao C, Liu S, Gao F, Zou Y, Ren Z, Yu Z (2022) The role of tumor microenvironment reprogramming in primary liver cancer chemotherapy resistance. Front Oncol 12:1008902PubMedPubMedCentralCrossRef Zhao C, Liu S, Gao F, Zou Y, Ren Z, Yu Z (2022) The role of tumor microenvironment reprogramming in primary liver cancer chemotherapy resistance. Front Oncol 12:1008902PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Polidoro MA, Mikulak J, Cazzetta V, Lleo A, Mavilio D, Torzilli G et al (2020) Tumor microenvironment in primary liver tumors: a challenging role of natural killer cells. World J Gastroenterol 26(33):4900–4918PubMedPubMedCentralCrossRef Polidoro MA, Mikulak J, Cazzetta V, Lleo A, Mavilio D, Torzilli G et al (2020) Tumor microenvironment in primary liver tumors: a challenging role of natural killer cells. World J Gastroenterol 26(33):4900–4918PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Zhang QY, Ho DW, Tsui YM, Ng IO (2022) Single-cell transcriptomics of liver cancer: hype or insights? Cell Mol Gastroenterol Hepatol 14(3):513–525PubMedPubMedCentralCrossRef Zhang QY, Ho DW, Tsui YM, Ng IO (2022) Single-cell transcriptomics of liver cancer: hype or insights? Cell Mol Gastroenterol Hepatol 14(3):513–525PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Kotsiliti E, Leone V, Schuehle S, Govaere O, Li H, Wolf MJ et al (2023) Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling. J Hepatol 79(2):296–313PubMedPubMedCentralCrossRef Kotsiliti E, Leone V, Schuehle S, Govaere O, Li H, Wolf MJ et al (2023) Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling. J Hepatol 79(2):296–313PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Qin R, Zhao H, He Q, Li F, Li Y, Zhao H (2022) Advances in single-cell sequencing technology in the field of hepatocellular carcinoma. Front Genet 13:996890PubMedPubMedCentralCrossRef Qin R, Zhao H, He Q, Li F, Li Y, Zhao H (2022) Advances in single-cell sequencing technology in the field of hepatocellular carcinoma. Front Genet 13:996890PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Ma L, Heinrich S, Wang L, Keggenhoff FL, Khatib S, Forgues M et al (2022) Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer. Nat Commun 13(1):7533PubMedPubMedCentralCrossRef Ma L, Heinrich S, Wang L, Keggenhoff FL, Khatib S, Forgues M et al (2022) Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer. Nat Commun 13(1):7533PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Zhao N, Dang H, Ma L, Martin SP, Forgues M, Ylaya K et al (2021) Intratumoral γδ T-cell infiltrates, chemokine (C-C Motif) ligand 4/chemokine (C-C Motif) ligand 5 protein expression and survival in patients with hepatocellular carcinoma. Hepatology (Baltimore, MD) 73(3):1045–1060PubMedCrossRef Zhao N, Dang H, Ma L, Martin SP, Forgues M, Ylaya K et al (2021) Intratumoral γδ T-cell infiltrates, chemokine (C-C Motif) ligand 4/chemokine (C-C Motif) ligand 5 protein expression and survival in patients with hepatocellular carcinoma. Hepatology (Baltimore, MD) 73(3):1045–1060PubMedCrossRef
14.
Zurück zum Zitat Scheiner B, Pinato DJ (2023) Tumor-infiltrating neutrophils: gatekeepers in liver cancer immune control. Gastroenterology 164(7):1338–1339PubMedCrossRef Scheiner B, Pinato DJ (2023) Tumor-infiltrating neutrophils: gatekeepers in liver cancer immune control. Gastroenterology 164(7):1338–1339PubMedCrossRef
15.
Zurück zum Zitat Wu F, Fan J, He Y, Xiong A, Yu J, Li Y et al (2021) Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nat Commun 12(1):2540PubMedPubMedCentralCrossRef Wu F, Fan J, He Y, Xiong A, Yu J, Li Y et al (2021) Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nat Commun 12(1):2540PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Xue R, Zhang Q, Cao Q, Kong R, Xiang X, Liu H et al (2022) Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature 612(7938):141–147PubMedCrossRef Xue R, Zhang Q, Cao Q, Kong R, Xiang X, Liu H et al (2022) Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature 612(7938):141–147PubMedCrossRef
17.
Zurück zum Zitat Forner A, Reig M, Bruix J (2018) Hepatocellular carcinoma. Lancet (London, England) 391(10127):1301–1314PubMedCrossRef Forner A, Reig M, Bruix J (2018) Hepatocellular carcinoma. Lancet (London, England) 391(10127):1301–1314PubMedCrossRef
18.
Zurück zum Zitat Yang JD, Heimbach JK (2020) New advances in the diagnosis and management of hepatocellular carcinoma. BMJ (Clinical Research Ed) 371:m3544PubMed Yang JD, Heimbach JK (2020) New advances in the diagnosis and management of hepatocellular carcinoma. BMJ (Clinical Research Ed) 371:m3544PubMed
19.
Zurück zum Zitat Bruix J, Reig M, Sherman M (2016) Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 150(4):835–853PubMedCrossRef Bruix J, Reig M, Sherman M (2016) Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 150(4):835–853PubMedCrossRef
20.
Zurück zum Zitat Oura K, Morishita A, Tani J, Masaki T (2021) Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review. Int J Mol Sci 22(11):5801PubMedPubMedCentralCrossRef Oura K, Morishita A, Tani J, Masaki T (2021) Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review. Int J Mol Sci 22(11):5801PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Wang X, Hassan W, Jabeen Q, Khan GJ, Iqbal F (2018) Interdependent and independent multidimensional role of tumor microenvironment on hepatocellular carcinoma. Cytokine 103:150–159PubMedCrossRef Wang X, Hassan W, Jabeen Q, Khan GJ, Iqbal F (2018) Interdependent and independent multidimensional role of tumor microenvironment on hepatocellular carcinoma. Cytokine 103:150–159PubMedCrossRef
23.
Zurück zum Zitat Ng MSF, Tan L, Wang Q, Mackay CR, Ng LG (2021) Neutrophils in cancer-unresolved questions. Sci China Life Sci 64(11):1829–1841PubMedCrossRef Ng MSF, Tan L, Wang Q, Mackay CR, Ng LG (2021) Neutrophils in cancer-unresolved questions. Sci China Life Sci 64(11):1829–1841PubMedCrossRef
24.
Zurück zum Zitat Zhang X, Zhang W, Yuan X, Fu M, Qian H, Xu W (2016) Neutrophils in cancer development and progression: roles, mechanisms, and implications (Review). Int J Oncol 49(3):857–867PubMedCrossRef Zhang X, Zhang W, Yuan X, Fu M, Qian H, Xu W (2016) Neutrophils in cancer development and progression: roles, mechanisms, and implications (Review). Int J Oncol 49(3):857–867PubMedCrossRef
25.
Zurück zum Zitat Chen H, Zhou XH, Li JR, Zheng TH, Yao FB, Gao B et al (2021) Neutrophils: driving inflammation during the development of hepatocellular carcinoma. Cancer Lett 522:22–31PubMedCrossRef Chen H, Zhou XH, Li JR, Zheng TH, Yao FB, Gao B et al (2021) Neutrophils: driving inflammation during the development of hepatocellular carcinoma. Cancer Lett 522:22–31PubMedCrossRef
26.
Zurück zum Zitat Geh D, Leslie J, Rumney R, Reeves HL, Bird TG, Mann DA (2022) Neutrophils as potential therapeutic targets in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 19(4):257–273PubMedCrossRef Geh D, Leslie J, Rumney R, Reeves HL, Bird TG, Mann DA (2022) Neutrophils as potential therapeutic targets in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 19(4):257–273PubMedCrossRef
27.
28.
Zurück zum Zitat Li XY, Shen Y, Zhang L, Guo X, Wu J (2022) Understanding initiation and progression of hepatocellular carcinoma through single cell sequencing. Biochim Biophys Acta 1877(3):188720 Li XY, Shen Y, Zhang L, Guo X, Wu J (2022) Understanding initiation and progression of hepatocellular carcinoma through single cell sequencing. Biochim Biophys Acta 1877(3):188720
29.
Zurück zum Zitat Arvanitakis K, Mitroulis I, Germanidis G (2021) Tumor-associated neutrophils in hepatocellular carcinoma pathogenesis, prognosis, and therapy. Cancers 13(12):2899PubMedPubMedCentralCrossRef Arvanitakis K, Mitroulis I, Germanidis G (2021) Tumor-associated neutrophils in hepatocellular carcinoma pathogenesis, prognosis, and therapy. Cancers 13(12):2899PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Liu L, Zhang R, Deng J, Dai X, Zhu X, Fu Q et al (2022) Construction of TME and Identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma. Cancer Immunol Immunother : CII 71(1):121–136PubMedCrossRef Liu L, Zhang R, Deng J, Dai X, Zhu X, Fu Q et al (2022) Construction of TME and Identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma. Cancer Immunol Immunother : CII 71(1):121–136PubMedCrossRef
31.
Zurück zum Zitat Liu Y, Xun Z, Ma K, Liang S, Li X, Zhou S et al (2023) Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol 78(4):770–782PubMedCrossRef Liu Y, Xun Z, Ma K, Liang S, Li X, Zhou S et al (2023) Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol 78(4):770–782PubMedCrossRef
32.
Zurück zum Zitat Hu J, Zhang L, Xia H, Yan Y, Zhu X, Sun F et al (2023) Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. Genome Medicine 15(1):14PubMedPubMedCentralCrossRef Hu J, Zhang L, Xia H, Yan Y, Zhu X, Sun F et al (2023) Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. Genome Medicine 15(1):14PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Eun JW, Yoon JH, Ahn HR, Kim S, Kim YB, Lim SB et al (2023) Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib. Cancer Commun (London, England) 43(4):455–479CrossRef Eun JW, Yoon JH, Ahn HR, Kim S, Kim YB, Lim SB et al (2023) Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib. Cancer Commun (London, England) 43(4):455–479CrossRef
34.
Zurück zum Zitat Hu J, Yang L, Peng X, Mao M, Liu X, Song J et al (2022) ALDH2 hampers immune escape in liver hepatocellular carcinoma through ROS/Nrf2-mediated autophagy. Inflammation 45(6):2309–2324PubMedCrossRef Hu J, Yang L, Peng X, Mao M, Liu X, Song J et al (2022) ALDH2 hampers immune escape in liver hepatocellular carcinoma through ROS/Nrf2-mediated autophagy. Inflammation 45(6):2309–2324PubMedCrossRef
35.
Zurück zum Zitat Zhang H, Fu L (2021) The role of ALDH2 in tumorigenesis and tumor progression: targeting ALDH2 as a potential cancer treatment. Acta pharmaceutica Sinica B 11(6):1400–1411PubMedPubMedCentralCrossRef Zhang H, Fu L (2021) The role of ALDH2 in tumorigenesis and tumor progression: targeting ALDH2 as a potential cancer treatment. Acta pharmaceutica Sinica B 11(6):1400–1411PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Su Y, Xue C, Gu X, Wang W, Sun Y, Zhang R et al (2023) Identification of a novel signature based on macrophage-related marker genes to predict prognosis and immunotherapeutic effects in hepatocellular carcinoma. Front Oncol 13:1176572PubMedPubMedCentralCrossRef Su Y, Xue C, Gu X, Wang W, Sun Y, Zhang R et al (2023) Identification of a novel signature based on macrophage-related marker genes to predict prognosis and immunotherapeutic effects in hepatocellular carcinoma. Front Oncol 13:1176572PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Tao Z, Huang J, Li J. (2023) Comprehensive intratumoral heterogeneity landscaping of liver hepatocellular carcinoma and discerning of APLP2 in cancer progression. Environ Toxicol Tao Z, Huang J, Li J. (2023) Comprehensive intratumoral heterogeneity landscaping of liver hepatocellular carcinoma and discerning of APLP2 in cancer progression. Environ Toxicol
38.
Zurück zum Zitat Marengo A, Rosso C, Bugianesi E (2016) Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med 67:103–117PubMedCrossRef Marengo A, Rosso C, Bugianesi E (2016) Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med 67:103–117PubMedCrossRef
40.
Zurück zum Zitat Wang X, Huang H, Sze KM, Wang J, Tian L, Lu J et al (2023) S100A10 promotes HCC development and progression via transfer in extracellular vesicles and regulating their protein cargos. Gut 72(7):1370–1384PubMedCrossRef Wang X, Huang H, Sze KM, Wang J, Tian L, Lu J et al (2023) S100A10 promotes HCC development and progression via transfer in extracellular vesicles and regulating their protein cargos. Gut 72(7):1370–1384PubMedCrossRef
41.
Zurück zum Zitat Zhou X, Shi M, Cao J, Yuan T, Yu G, Chen Y et al (2021) S100 calcium binding protein A10, A novel oncogene, promotes the proliferation, invasion, and migration of hepatocellular carcinoma. Front Genet 12:695036PubMedPubMedCentralCrossRef Zhou X, Shi M, Cao J, Yuan T, Yu G, Chen Y et al (2021) S100 calcium binding protein A10, A novel oncogene, promotes the proliferation, invasion, and migration of hepatocellular carcinoma. Front Genet 12:695036PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Mukai Y, Yamaguchi A, Sakuma T, Nadai T, Furugen A, Narumi K et al (2022) Involvement of SLC16A1/MCT1 and SLC16A3/MCT4 in l-lactate transport in the hepatocellular carcinoma cell line. Biopharm Drug Dispos 43(5):183–191PubMedCrossRef Mukai Y, Yamaguchi A, Sakuma T, Nadai T, Furugen A, Narumi K et al (2022) Involvement of SLC16A1/MCT1 and SLC16A3/MCT4 in l-lactate transport in the hepatocellular carcinoma cell line. Biopharm Drug Dispos 43(5):183–191PubMedCrossRef
43.
Zurück zum Zitat Jiang Z, Zhou X, Li R, Michal JJ, Zhang S, Dodson MV et al (2015) Whole transcriptome analysis with sequencing: methods, challenges and potential solutions. Cellular Mol Life Sci : CMLS 72(18):3425–3439PubMedCrossRef Jiang Z, Zhou X, Li R, Michal JJ, Zhang S, Dodson MV et al (2015) Whole transcriptome analysis with sequencing: methods, challenges and potential solutions. Cellular Mol Life Sci : CMLS 72(18):3425–3439PubMedCrossRef
44.
Zurück zum Zitat Yang LY, Luo Q, Lu L, Zhu WW, Sun HT, Wei R et al (2020) Increased neutrophil extracellular traps promote metastasis potential of hepatocellular carcinoma via provoking tumorous inflammatory response. J Hematol Oncol 13(1):3PubMedPubMedCentralCrossRef Yang LY, Luo Q, Lu L, Zhu WW, Sun HT, Wei R et al (2020) Increased neutrophil extracellular traps promote metastasis potential of hepatocellular carcinoma via provoking tumorous inflammatory response. J Hematol Oncol 13(1):3PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Du D, Liu C, Qin M, Zhang X, Xi T, Yuan S et al (2022) Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharmaceutica Sinica B 12(2):558–580PubMedCrossRef Du D, Liu C, Qin M, Zhang X, Xi T, Yuan S et al (2022) Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharmaceutica Sinica B 12(2):558–580PubMedCrossRef
46.
Zurück zum Zitat Sin SQ, Mohan CD, Goh RMW, You M, Nayak SC, Chen L, et al. (2022) Hypoxia signaling in hepatocellular carcinoma: challenges and therapeutic opportunities. Cancer metastasis reviews Sin SQ, Mohan CD, Goh RMW, You M, Nayak SC, Chen L, et al. (2022) Hypoxia signaling in hepatocellular carcinoma: challenges and therapeutic opportunities. Cancer metastasis reviews
47.
Zurück zum Zitat Wang L, Liu Y, Dai Y, Tang X, Yin T, Wang C et al (2023) Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment. Gut 72(5):958–971PubMedCrossRef Wang L, Liu Y, Dai Y, Tang X, Yin T, Wang C et al (2023) Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment. Gut 72(5):958–971PubMedCrossRef
48.
Zurück zum Zitat Xia S, Pan Y, Liang Y, Xu J, Cai X (2020) The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine 51:102610PubMedPubMedCentralCrossRef Xia S, Pan Y, Liang Y, Xu J, Cai X (2020) The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine 51:102610PubMedPubMedCentralCrossRef
49.
Zurück zum Zitat Zeng Q, Klein C, Caruso S, Maille P, Laleh NG, Sommacale D et al (2022) Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology. J Hepatol 77(1):116–127PubMedCrossRef Zeng Q, Klein C, Caruso S, Maille P, Laleh NG, Sommacale D et al (2022) Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology. J Hepatol 77(1):116–127PubMedCrossRef
Metadaten
Titel
Comprehensive analysis of scRNA-Seq and bulk RNA-Seq data reveals dynamic changes in tumor-associated neutrophils in the tumor microenvironment of hepatocellular carcinoma and leads to the establishment of a neutrophil-related prognostic model
verfasst von
Dashuai Yang
Yu Zhou
Yanbing Zhang
Yang Su
Jie Shen
Bin Yu
Kailiang Zhao
Youming Ding
Publikationsdatum
25.11.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 12/2023
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-023-03567-4

Weitere Artikel der Ausgabe 12/2023

Cancer Immunology, Immunotherapy 12/2023 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.